Experimental & Developmental Therapeutics (EDT) Research Program

Translation of mechanism-based therapies to the clinic

Aim 1

To conduct IND-enabling preclinical studies of antitumor agents

Aim 2

To conduct mechanism-based clinical trials

Xiongbin Lu, PhD

A recent article in Science Translational Medicine detailed the discovery of a game-changing antibody-drug conjugate for treating HER2-low triple negative breast cancer.

Senior author and EDT co-program leader Xiongbin Lu, PhD, and his team combined trastuzumab—a targeted cancer drug for HER2-positive breast cancer patients—with the small-molecule inhibitor α-amanitin to create a novel drug called T-Ama.

More about T-Ama

Sherif Farag, MD, PhD

A team of IU researchers led by Sherif Farag, MD, PhD, found that using a drug approved for Type 2 diabetes reduces the risk of acute graft-versus-host disease (GVHD), one of the most serious complications of blood stem cell transplantation.

Their study was published in the January 2021 issue of the prestigious New England Journal of Medicine, highlighted with an editorial by Fred Hutchinson Cancer Research Center’s Paul J. Martin, MD.

Study Details

Team Science: National leaders in cancer research

Patrick Loehrer, MD

Patrick Loehrer, MD

Expertise: Thymoma and thymic carcinoma

Meet Dr. Loehrer
Kathy Miller, MD

Kathy Miller, MD

Expertise: Breast cancer clinical trials

Meet Dr. Miller
Richard Zellars, MD

Richard Zellars, MD

Expertise: Radiation oncology

Meet Dr. Zellars
Timothy Corson, PhD

Timothy Corson, PhD

Expertise: Retinoblastoma

Meet Dr. Corson
Mateusz Opyrchal, MD, PhD

Mateusz Opyrchal, MD, PhD

Expertise: Metastatic breast cancer

Meet Dr. Opyrchal


Support Our Research